Focusing on the impact of the PNPLA3 genotype on lifestyle interventions in NAFLD patients, one study showed that mutated patients were more sensitive to the beneficial effect of lifestyle modification on steatosis reduction, rather than wildtype patients [62]. The gene discussed is PNPLA3; the disease is metabolic dysfunction-associated steatotic liver disease.